Cancer Family
Reproductive System Neoplasm
CI-CAN-00000338Explore in graph →
Non-malignant3,041 active trials38 approved drugs197 evidence items
- NCIt
- C3674
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000338Explore in graph →
Clinical trials
13,668 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04067960 | Pharmacogenomics Testing in the Optimal Use of Supportive Care Medications in Stage III-IV Cancer | completed | Early Phase 1 | 197 | Mayo ClinicOTHER | 1 | Aug 14, 2024 | clinicaltrials |
| NCT06546527 | Study of [177Lu]Lu-PSMA-137 In Metastatic Castrate Resistant Prostate Cancer（mCRPC） | not yet recruiting | Early Phase 1 | 12 | Peking University First HospitalOTHER | 0 | Aug 9, 2024 | clinicaltrials |
| NCT05549024 |
| 68Ga-RM26-RGD PET/CT Imaging in the GRPR and αvβ3 Positive Tumor Patients |
| recruiting |
| Early Phase 1 |
| 90 |
| Peking Union Medical College HospitalOTHER |
| 1 |
| Jul 5, 2024 |
| clinicaltrials |
| NCT06462495 | Head-to-head Comparison of [18F]F-PSMA-N5 With [18F]F-PSMA-1007 PET/CT in PCa Diagnosis, Recurrence, and Metastasis | unknown | Early Phase 1 | 30 | Anhui Provincial HospitalOTHER_GOV | 1 | Jun 17, 2024 | clinicaltrials |
| NCT06462508 | Head-to-head Comparison of [18F]F-PSMA-N5 With [68Ga]Ga-PSMA-11 PET/CT in PCa Diagnosis, Recurrence, and Metastasis | unknown | Early Phase 1 | 30 | Anhui Provincial HospitalOTHER_GOV | 1 | Jun 17, 2024 | clinicaltrials |
| NCT03275857 | Cisplatin in Castration Resistant Prostate Cancer | completed | Early Phase 1 | 12 | University of RochesterOTHER | 1 | Jun 10, 2024 | clinicaltrials |
| NCT06437496 | 68Ga-AAZTA-093 PET/CT: First-in-human Study | unknown | Early Phase 1 | 30 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | May 31, 2024 | clinicaltrials |
| NCT02113657 | T-Cell Responses to Neoantigens Post Treatment With Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer | completed | Early Phase 1 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | May 24, 2024 | clinicaltrials |
| NCT03358563 | Pilot Trial of Chemohormonal Therapy Followed by Prostatectomy in High Risk Prostate Cancer | completed | Early Phase 1 | 30 | University of Wisconsin, MadisonOTHER | 1 | May 3, 2024 | clinicaltrials |
| NCT04726033 | 64Cu-TLX592 Phase I Safety, PK, Biodistribution and Dosimetry Study (CUPID Study)(CUPID) | completed | Early Phase 1 | 14 | Telix Pharmaceuticals (Innovations) Pty LimitedINDUSTRY | 1 | May 1, 2024 | clinicaltrials |
| NCT02728830 | A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers | completed | Early Phase 1 | 39 | AA SecordOTHER | 1 | Feb 21, 2024 | clinicaltrials |
| NCT05238831 | SMMART Adaptive Clinical Treatment (ACT) Trial | withdrawn | Early Phase 1 | 0 | OHSU Knight Cancer InstituteOTHER | 0 | Jan 23, 2024 | clinicaltrials |
| NCT05773703 | Exploratory PK and Imaging Study of PSMA-Targeted Trillium Compounds and PTI-122 in Metastatic Prostate Cancer | completed | Early Phase 1 | 23 | Ratio Therapeutics, Inc.INDUSTRY | 1 | Dec 13, 2023 | clinicaltrials |
| NCT03694834 | Window of Opportunity Pilot Study of Pembrolizumab in Obesity-driven Endometrial Cancer | terminated | Early Phase 1 | 3 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Nov 28, 2023 | clinicaltrials |
| NCT05725070 | Phase 0/1 Study of 212Pb-NG001 in mCRPC | completed | Early Phase 1 | 3 | ARTBIO Inc.INDUSTRY | 1 | Oct 6, 2023 | clinicaltrials |
| NCT05567679 | A Study of Tazemetostat (Tazverik) Before Prostatectomy in Men With Prostate Cancer | withdrawn | Early Phase 1 | 0 | Edwin Posadas, MDOTHER | 1 | Sep 22, 2023 | clinicaltrials |
| NCT06050239 | Study of 177Lu-PSMA-0057 in Metastatic Prostate Cancer | unknown | Early Phase 1 | 10 | Nanjing First Hospital, Nanjing Medical UniversityOTHER | 1 | Sep 22, 2023 | clinicaltrials |
| NCT04831541 | 68Ga-PSMA-11 PET/CT in Patients With Various Types of Cancer | unknown | Early Phase 1 | 600 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT01253213 | BR55 in Prostate Cancer: an Exploratory Clinical Trial | completed | Early Phase 1 | 26 | Bracco Diagnostics, IncINDUSTRY | 1 | Aug 1, 2023 | clinicaltrials |
| NCT05558956 | Total Body PET-CT Imaging of Prostate Cancer Using Illuccix | unknown | Early Phase 1 | 100 | BAMF HealthOTHER | 1 | Jul 27, 2023 | clinicaltrials |
| NCT05961111 | A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Advanced Solid Tumors | unknown | Early Phase 1 | 20 | Shanghai Yunying Medical TechnologyINDUSTRY | 1 | Jul 27, 2023 | clinicaltrials |
| NCT05955677 | Head-to-head Comparison of [68Ga]Ga-PSMA-D5 With [68Ga]Ga-PSMA-11 PET/CT in PCa Diagnosis, Recurrence, and Metastasis | unknown | Early Phase 1 | 100 | Anhui Provincial HospitalOTHER_GOV | 1 | Jul 21, 2023 | clinicaltrials |
| NCT02391025 | Gallium-68 Citrate PET Used in Prostate Cancer | completed | Early Phase 1 | 39 | Rahul AggarwalOTHER | 1 | Jun 18, 2023 | clinicaltrials |
| NCT05886075 | A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Advanced Solid Tumors | unknown | Early Phase 1 | 24 | Shanghai Yunying Medical TechnologyINDUSTRY | 1 | Jun 2, 2023 | clinicaltrials |
| NCT05860374 | A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Solid Tumors | unknown | Early Phase 1 | 20 | Shanghai Yunying Medical TechnologyINDUSTRY | 1 | May 16, 2023 | clinicaltrials |
| NCT04658849 | Insulin Resistance Following ADT for Prostate CA | withdrawn | Early Phase 1 | 0 | St. Louis UniversityOTHER | 1 | May 15, 2023 | clinicaltrials |
| NCT05368506 | ZN-c3 for the Treatment of Metastatic Triple-Negative Breast Cancer and Advanced Ovarian Cancer | withdrawn | Early Phase 1 | 0 | OHSU Knight Cancer InstituteOTHER | 0 | May 6, 2023 | clinicaltrials |
| NCT03927651 | ICG to Assess Ovarian Perfusion | completed | Early Phase 1 | 54 | Northwestern UniversityOTHER | 1 | Apr 18, 2023 | clinicaltrials |
| NCT04158817 | 68Ga-THP-PSMA PET/CT in Prostate Cancer: Clinical Stage and Restage | completed | Early Phase 1 | 8 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Apr 18, 2023 | clinicaltrials |
| NCT05815394 | 177Lu-labeled NY108 SPECT Imaging in Patients | unknown | Early Phase 1 | 10 | Affiliated Hospital of Jiangnan UniversityOTHER | 1 | Apr 18, 2023 | clinicaltrials |
| NCT05812677 | A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Cervical and Endometrial Cancer | unknown | Early Phase 1 | 20 | Shanghai Yunying Medical TechnologyINDUSTRY | 1 | Apr 14, 2023 | clinicaltrials |
| NCT04282967 | Streaming Web-based Exercise At Home: A Pilot Study | completed | Early Phase 1 | 12 | Celina ShirazipourOTHER | 1 | Apr 11, 2023 | clinicaltrials |
| NCT04976257 | Pharmacokinetics of IA and IV Ga68-PSMA-11 Infusion | completed | Early Phase 1 | 5 | Ryan Kohlbrenner, MDOTHER | 1 | Apr 7, 2023 | clinicaltrials |
| NCT05801783 | A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Ovarian Cancer | unknown | Early Phase 1 | 10 | Shanghai Yunying Medical TechnologyINDUSTRY | 1 | Apr 6, 2023 | clinicaltrials |
| NCT04041128 | PARP Inhibition During Pre-surgical Window in Breast/Ovary Cancer | completed | Early Phase 1 | 14 | University of Texas Southwestern Medical CenterOTHER | 1 | Mar 20, 2023 | clinicaltrials |
| NCT02534376 | Cellular Effect of Cholesterol-Lowering Prior to Prostate Removal | completed | Early Phase 1 | 63 | Cedars-Sinai Medical CenterOTHER | 1 | Feb 22, 2023 | clinicaltrials |
| NCT02826382 | Preliminary Evaluation of Uptake in Bone Metastases and Biodistribution of [68Ga]P15-041 | completed | Early Phase 1 | 14 | Five Eleven Pharma, Inc.INDUSTRY | 1 | Jan 12, 2023 | clinicaltrials |
| NCT02013492 | Propranolol Hydrochloride in Treating Patients With Locally Recurrent or Metastatic Solid Tumors That Cannot Be Removed By Surgery | completed | Early Phase 1 | 1 | William CarsonOTHER | 1 | Dec 6, 2022 | clinicaltrials |
| NCT03692663 | Study of Anti-PSMA CAR NK Cell (TABP EIC) in Metastatic Castration-Resistant Prostate Cancer | unknown | Early Phase 1 | 9 | Allife Medical Science and Technology Co., Ltd.INDUSTRY | 1 | Aug 1, 2022 | clinicaltrials |
| NCT04996602 | Therapeutic Efficiency and Response to 2.0 GBq (55mCi) 177Lu-EB-PSMA in Patients With mCRPC | unknown | Early Phase 1 | 30 | Peking Union Medical College HospitalOTHER | 1 | Jul 15, 2022 | clinicaltrials |
| NCT04288336 | Daily, Long-Term Intermittent Fasting for the Prevention of PSA-Recurrence in Patients With Localized Prostate Cancer After Radical Prostatectomy | withdrawn | Early Phase 1 | 0 | Mayo ClinicOTHER | 1 | Jul 11, 2022 | clinicaltrials |
| NCT03382574 | Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-Oophorectomy | terminated | Early Phase 1 | 2 | National Cancer Institute (NCI)NIH | 2 | Jun 14, 2022 | clinicaltrials |
| NCT04266392 | Molecular Imaging of Prostate Cancer Using Radiofluorinated PSMA Ligand | completed | Early Phase 1 | 20 | Stony Brook UniversityOTHER | 1 | May 5, 2022 | clinicaltrials |
| NCT03028519 | Vitamin D, Leptin, Vitamin D Receptor Polymorphism, and Treatment-Related Morbidity in Ovarian Cancer | completed | Early Phase 1 | 81 | University of OklahomaOTHER | 1 | Apr 19, 2022 | clinicaltrials |
| NCT03071328 | INJECT: A Pilot Study of Intra-tumoral Injections in Metastatic Urological Cancers | completed | Early Phase 1 | 10 | Duke UniversityOTHER | 1 | Apr 11, 2022 | clinicaltrials |
| NCT05087264 | Clinical Study of Indocyanine Green Displaying Pelvic Nerve in Radical Operation of Cervical Cancer | unknown | Early Phase 1 | 86 | Fifth Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Mar 18, 2022 | clinicaltrials |
| NCT01979003 | Efficacy of Fluorescein Visualization of the Uterus in Detecting Endometrial Cancer Invasion | completed | Early Phase 1 | 100 | University of ArkansasOTHER | 1 | Feb 24, 2022 | clinicaltrials |
| NCT02316834 | Talazoparib in Determining Genetic Effects on Disease Response in Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer(POSITION) | completed | Early Phase 1 | 4 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 24, 2022 | clinicaltrials |
| NCT02855697 | Multi-maintenance Olaparib After Disease Recurrence in Participants With Platinum Sensitive BRCAm High Grade Serous Ovarian Cancer(MOLTO) | completed | Early Phase 1 | 28 | The Christie NHS Foundation TrustOTHER | 1 | Feb 22, 2022 | clinicaltrials |
| NCT05180851 | Safety and Efficacy of Recombinant Oncolytic Adenovirus L-IFN Injection in Relapsed/Refractory Solid Tumors Clinical Study(YSCH-01) | unknown | Early Phase 1 | 28 | Shanghai Fengxian District Central HospitalOTHER | 1 | Feb 1, 2022 | clinicaltrials |
Data updated 22 days agoSource updated Aug 14, 2024source: clinicaltrials